Ipratropiumbromide Sandoz (Ipratropium Bromide)

Ipratropium bromide works by competitively blocking muscarinic (M3) receptors on airway smooth muscle. This inhibition prevents acetylcholine‑induced bronchoconstriction, leading to relaxation of the bronchial muscles, bronchodilation, and improved airflow in patients with obstructive lung conditions.

The appropriate dose of Ipratropiumbromide Sandoz is determined by the prescribing healthcare professional based on the individual’s disease severity, response to therapy, and clinical guidelines. Patients should follow the specific instructions provided by their prescriber and the product’s labeling.

Safety data for ipratropium bromide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh the potential benefits against possible risks before prescribing to pregnant or nursing women, and use only if clearly needed.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ipratropium bromide is a short‑acting anticholinergic that provides bronchodilation by blocking muscarinic receptors, whereas β2‑agonists (e.g., albuterol) stimulate β2 receptors to relax airway smooth muscle. Ipratropium is often used in combination with β2‑agonists for additive effect, and it may be preferred in patients who experience tachycardia with β2‑agonists.

The inhalation formulation should be stored at room temperature below 25 °C, protected from light and moisture, and kept in its original packaging. Do not freeze the product. Ensure the device or vial is sealed until use to maintain sterility and potency.

Ipratropiumbromide is administered via inhalation using a nebulizer or metered‑dose inhaler, as directed by a healthcare professional. The patient inhales the prescribed number of puffs or nebulized dose, typically multiple times per day, ensuring proper technique to maximize drug delivery to the lungs.

Serious but rare risks include paradoxical bronchospasm, which can worsen breathing, and angioedema, a rapid swelling of the face, lips, tongue, or throat that may compromise airway. Immediate medical attention is required if any signs of these reactions occur.

Patients with a known hypersensitivity to ipratropium bromide, atropine, or any component of the formulation should avoid its use. Caution is also advised for individuals with narrow‑angle glaucoma, urinary retention, or severe gastrointestinal obstruction, as anticholinergic effects may exacerbate these conditions.